Pfizer Divests Its Swine Vaccine Business To Harbin Pharmaceutical Group In China As Condition Of $68 Billion Merger With Wyeth
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Pfizer recently completed the divestment of its swine vaccine business in China to local company Harbin Bio-Vaccine, an animal health subsidiary of Harbin Pharmaceutical Group
You may also be interested in...
Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition
With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.
Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition
With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B, Widening Nestle’s Reach In Emerging Markets
Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.